Tatva Chintan Pharma Chem Q1FY27 Results: Revenue Up 43% to ₹1,671 Mn, PAT Jumps 140%
Tatva Chintan Pharma Chem reported Q1FY27 results with revenue from operations at ₹1,671 Mn, a 43% YoY increase. PAT surged 140% to ₹160 Mn. EBITDA grew 86% to ₹323 Mn. The company highlighted strong performance across its product segments, including PTC, SDA, ESS, and PASC.
The substantial increase in revenue and profit, as detailed in the investor presentation, is a material event for the company and its investors.
The company reported significant year-on-year growth in revenue and profit, indicating a positive financial performance.
Tatva Chintan Pharma Chem Limited has released its investor presentation for the quarter ended June 30, 2026 (Q1FY27). The company reported a significant increase in its financial performance, with revenue from operations growing by 43% year-on-year to ₹1,671 million (Mn). Profit After Tax (PAT) saw a substantial surge of 140%, reaching ₹160 million. The EBITDA also grew by 86% to ₹323 million, with the EBITDA margin improving to 19% from 15% in the previous year's quarter. Consolidated financial highlights for Q1FY27 show revenue from operations at ₹1,671 Mn, up 43% YoY, and PAT at ₹160 Mn, up 140% YoY. The company's product portfolio includes Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts (ESS), and Pharma & Agrochemical Intermediates (PASC). In Q1FY27, PTC contributed 26% to revenue, SDA 35%, ESS 4%, and PASC 34%. The presentation also detailed the company's integrated manufacturing facilities, R&D capabilities, and commitment to green chemistry processes.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.